JP2010508816A - Ａｌｋ１受容体およびリガンドアンタゴニストならびにその使用 - Google Patents

Ａｌｋ１受容体およびリガンドアンタゴニストならびにその使用 Download PDF

Info

Publication number
JP2010508816A
JP2010508816A JP2009535341A JP2009535341A JP2010508816A JP 2010508816 A JP2010508816 A JP 2010508816A JP 2009535341 A JP2009535341 A JP 2009535341A JP 2009535341 A JP2009535341 A JP 2009535341A JP 2010508816 A JP2010508816 A JP 2010508816A
Authority
JP
Japan
Prior art keywords
alk1
antibody
polypeptide
seq
binds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2009535341A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010508816A5 (enExample
Inventor
アシャ グリンバーグ，
ジョン クノップフ，
ラビンドラ クマー，
ロバート スコット ピアーソル，
ジャスバー セーラ，
Original Assignee
アクセルロン ファーマ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アクセルロン ファーマ， インコーポレイテッド filed Critical アクセルロン ファーマ， インコーポレイテッド
Publication of JP2010508816A publication Critical patent/JP2010508816A/ja
Publication of JP2010508816A5 publication Critical patent/JP2010508816A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
JP2009535341A 2006-11-02 2007-11-02 Ａｌｋ１受容体およびリガンドアンタゴニストならびにその使用 Withdrawn JP2010508816A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85659206P 2006-11-02 2006-11-02
PCT/US2007/023217 WO2008057461A2 (en) 2006-11-02 2007-11-02 Alk1 receptor and ligand antagonists and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013142324A Division JP2013199496A (ja) 2006-11-02 2013-07-08 Ａｌｋ１受容体およびリガンドアンタゴニストならびにその使用

Publications (2)

Publication Number Publication Date
JP2010508816A true JP2010508816A (ja) 2010-03-25
JP2010508816A5 JP2010508816A5 (enExample) 2010-12-24

Family

ID=39365087

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2009535341A Withdrawn JP2010508816A (ja) 2006-11-02 2007-11-02 Ａｌｋ１受容体およびリガンドアンタゴニストならびにその使用
JP2013142324A Withdrawn JP2013199496A (ja) 2006-11-02 2013-07-08 Ａｌｋ１受容体およびリガンドアンタゴニストならびにその使用
JP2015089239A Expired - Fee Related JP6348448B2 (ja) 2006-11-02 2015-04-24 Ａｌｋ１受容体およびリガンドアンタゴニストならびにその使用
JP2018071503A Withdrawn JP2018127471A (ja) 2006-11-02 2018-04-03 Ａｌｋ１受容体およびリガンドアンタゴニストならびにその使用
JP2020108938A Pending JP2020150955A (ja) 2006-11-02 2020-06-24 Ａｌｋ１受容体およびリガンドアンタゴニストならびにその使用

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2013142324A Withdrawn JP2013199496A (ja) 2006-11-02 2013-07-08 Ａｌｋ１受容体およびリガンドアンタゴニストならびにその使用
JP2015089239A Expired - Fee Related JP6348448B2 (ja) 2006-11-02 2015-04-24 Ａｌｋ１受容体およびリガンドアンタゴニストならびにその使用
JP2018071503A Withdrawn JP2018127471A (ja) 2006-11-02 2018-04-03 Ａｌｋ１受容体およびリガンドアンタゴニストならびにその使用
JP2020108938A Pending JP2020150955A (ja) 2006-11-02 2020-06-24 Ａｌｋ１受容体およびリガンドアンタゴニストならびにその使用

Country Status (14)

Country Link
US (4) US8455428B2 (enExample)
EP (2) EP2087001B1 (enExample)
JP (5) JP2010508816A (enExample)
KR (3) KR20170012582A (enExample)
CN (2) CN111518218A (enExample)
AU (1) AU2007317926A1 (enExample)
BR (1) BRPI0717964A2 (enExample)
CA (1) CA2668411C (enExample)
DK (1) DK2087001T3 (enExample)
ES (1) ES2612755T3 (enExample)
IL (2) IL198522A (enExample)
MX (1) MX2009004718A (enExample)
RU (2) RU2559532C2 (enExample)
WO (1) WO2008057461A2 (enExample)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016036322A (ja) * 2014-08-11 2016-03-22 日本化薬株式会社 血管新生因子と結合するキメラタンパク質
JP2018070625A (ja) * 2011-04-20 2018-05-10 アクセレロン ファーマ インコーポレイテッドＡｃｃｅｌｅｒｏｎ Ｐｈａｒｍａ，Ｉｎｃ． エンドグリンポリペプチドおよびその使用
JP2018517664A (ja) * 2015-04-06 2018-07-05 アクセルロン ファーマ， インコーポレイテッド シングルアームｉ型およびｉｉ型受容体融合タンパク質およびその使用
JP2018127471A (ja) * 2006-11-02 2018-08-16 アクセルロン ファーマ， インコーポレイテッド Ａｌｋ１受容体およびリガンドアンタゴニストならびにその使用
US11590201B2 (en) 2013-10-25 2023-02-28 Acceleron Pharma, Inc. Endoglin peptides to treat fibrotic diseases

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8764725B2 (en) 2004-02-09 2014-07-01 Covidien Lp Directional anchoring mechanism, method and applications thereof
WO2006091930A2 (en) * 2005-02-24 2006-08-31 Massachusetts Eye & Ear Infirmary Methods and compounds for promoting vessel regression
US8642031B2 (en) 2006-11-02 2014-02-04 Acceleron Pharma, Inc. Antagonists of BMP9, BMP10, ALK1 and other ALK1 ligands, and uses thereof
US10059756B2 (en) * 2006-11-02 2018-08-28 Acceleron Pharma Inc. Compositions comprising ALK1-ECD protein
CL2008003302A1 (es) * 2007-11-09 2009-03-06 Genentech Inc Uso de una proteina de funsion kinasa 1 similar al receptor de activina (alk-1) y fc (alk1.fc) porque sirve para preparar un medicamento contra tumor,cancer o desordenes proliferativos.
US7855564B2 (en) * 2008-02-14 2010-12-21 Delaware Capital Formation, Inc. Acoustic wave device physical parameter sensor
CN105963695A (zh) * 2008-05-02 2016-09-28 阿塞勒隆制药公司 用于调节血管发生和周细胞包裹的基于alk1拮抗剂的方法和组合物
EP2291401A2 (en) * 2008-05-15 2011-03-09 Acceleron Pharma, Inc. Antagonists of bmp9, bmp10, alk1 and other alk1 ligands, and uses thereof
WO2010126169A1 (ja) * 2009-04-30 2010-11-04 協和発酵キリン株式会社 Alk1阻害剤を有効成分とする血管障害を抑制するための医薬組成物
WO2011056494A1 (en) * 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations
KR101421171B1 (ko) * 2011-08-31 2014-07-22 재단법인 제이씨비 공동생물과학연구소 인간 골형성 단백질 수용체 1ａ의 세포외 도메인을 유효성분으로 포함하는 피부 상태 개선용 조성물
WO2013116781A1 (en) * 2012-02-02 2013-08-08 Acceleron Pharma Inc. Alk1 antagonists and their uses in treating renal cell carcinoma
AU2014388308A1 (en) * 2014-03-28 2016-10-27 Acceleron Pharma, Inc. Use of activin receptor-like kinase 1 (ALK-1) antagonists in the treatment of cancer
GB201412290D0 (en) * 2014-07-10 2014-08-27 Cambridge Entpr Ltd Novel use
EP3280435B1 (en) * 2015-04-06 2021-06-02 Acceleron Pharma Inc. Tgf-beta superfamily type i and type ii receptor heteromultimers and uses thereof
SG11201707815RA (en) * 2015-06-05 2017-12-28 Novartis Ag Antibodies targeting bone morphogenetic protein 9 (bmp9) and methods therefor
CN105254764A (zh) * 2015-08-27 2016-01-20 上海康岱生物医药技术有限公司 ACVR1-Fc融合蛋白及其制法和用途
US20210403549A1 (en) * 2017-05-17 2021-12-30 Yale University Compounds and compositions that inhibit or prevent lipoprotein entry into the endothelium
US12508262B2 (en) 2020-04-30 2025-12-30 Keros Therapeutics, Inc. Methods of using ALK2 inhibitors
WO2022098812A1 (en) 2020-11-04 2022-05-12 Keros Therapeutics, Inc. Methods of treating iron overload

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8529014D0 (en) 1985-11-25 1986-01-02 Biogen Nv Enhanced secretion of heterologous proteins
JPS63502716A (ja) 1986-03-07 1988-10-13 マサチューセッツ・インステチュート・オブ・テクノロジー 糖タンパク安定性の強化方法
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5096815A (en) 1989-01-06 1992-03-17 Protein Engineering Corporation Generation and selection of novel dna-binding proteins and polypeptides
US5198346A (en) 1989-01-06 1993-03-30 Protein Engineering Corp. Generation and selection of novel DNA-binding proteins and polypeptides
US5350836A (en) 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP0631584A4 (en) 1991-02-28 1998-07-01 Dana Farber Cancer Inst Inc DIAGNOSIS AND THERAPY OF CANCER.
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
US5288931A (en) 1991-12-06 1994-02-22 Genentech, Inc. Method for refolding insoluble, misfolded insulin-like growth factor-I into an active conformation
US5776427A (en) 1992-03-05 1998-07-07 Board Of Regents, The University Of Texas System Methods for targeting the vasculature of solid tumors
US5965132A (en) 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US5830847A (en) 1992-10-30 1998-11-03 Hsc Research & Development Limited Partnership Soluble TGF-β-binding endoglin polypeptides and homodimers
JPH08504577A (ja) 1992-10-30 1996-05-21 エイチエスシー リサーチ アンド ディベロプメント リミテッド パートナーシップ ＴＧＦ−βの制御活性を改変するための組成物および方法
US7592428B1 (en) 1992-11-17 2009-09-22 Ludwig Institute For Cancer Research Antibodies which bind specifically to activin receptor like kinases
US6692925B1 (en) 1992-11-17 2004-02-17 Ludwig Institute For Cancer Research Proteins having serine/threonine kinase domains, corresponding nucleic acid molecules, and their use
NZ257631A (en) 1992-11-17 1996-03-26 Ludwig Inst Cancer Res Serine/threonine kinase domain-containing protein, dna and hosts therefor
EP0690871A4 (en) 1993-01-12 1999-10-20 Univ Johns Hopkins Med GROWTH DIFFERENTIATION FACTOR-5
US5885573A (en) 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
US5541087A (en) 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
US5925351A (en) 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
JP2000514777A (ja) 1995-08-14 2000-11-07 クリエイティブ バイオモレキュールズ，インコーポレイテッド 骨形成タンパク質（ｏｐ−１）およびそのアナログの細胞表面レセプターａｌｋ−１およびそのアナログへの結合
EP0938505B1 (en) 1996-05-31 2002-03-06 Health Research, Inc. Anti-endoglin monoclonal antibodies and their use in anti-angiogenesis therapy
US6190660B1 (en) 1996-05-31 2001-02-20 Health Research, Inc. Anti-endoglin monoclonal antibodies and their use in antiangiogenic therapy
MX9701946A (es) 1997-03-14 1998-04-30 Arturo Jimenez Bayardo Solucion oftalmica transportadora.
WO1998047531A2 (en) 1997-04-21 1998-10-29 Arch Development Corporation Fc receptor non-binding anti-cd3 monoclonal antibodies deliver a partial tcr signal and induce clonal anergy
WO1999003992A1 (en) 1997-07-15 1999-01-28 Immunex Corporation Trail receptor
EP1071765A4 (en) 1998-03-13 2003-01-15 Ludwig Inst Cancer Res Alk-1 responds to tgf-beta and signals through smad-1 and smad-5
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
CA2323757C (en) 1998-04-02 2011-08-02 Genentech, Inc. Antibody variants and fragments thereof
US6413513B1 (en) 1998-05-22 2002-07-02 Entremed, Inc. Compositions and methods for inhibiting endothelial cell proliferation and regulating angiogenesis using cancer markers
US20030012792A1 (en) 1998-05-22 2003-01-16 Holaday John W. Compositions and methods for inhibiting endothelial cell proliferation and regulating angiogenesis using cancer markers
GB9912350D0 (en) 1999-05-26 1999-07-28 European Molecular Biology Lab Embl Modified cytokine
AU5306700A (en) * 1999-06-03 2000-12-28 Human Genome Sciences, Inc. Angiogenic proteins and uses thereof
US7067110B1 (en) 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
US7740841B1 (en) 2000-01-28 2010-06-22 Sunnybrook Health Science Center Therapeutic method for reducing angiogenesis
HRP20020751B1 (hr) 2000-02-15 2011-01-31 Sugen Pirolom supstituirani 2-indolinoni kao inhibitori protein kinaze
US7077836B2 (en) 2000-07-21 2006-07-18 Vein Rx, Inc. Methods and apparatus for sclerosing the wall of a varicose vein
CA2417982A1 (en) 2000-08-03 2002-02-14 The University Of Utah Research Foundation Manipulation of arterial-venous identity
DE10043481A1 (de) 2000-09-04 2002-04-11 Vectron Therapeutics Ag Imt Humaner Antikörper gegen Endoglin (CD105) und seine Verwendung
MXPA03005696A (es) 2000-12-21 2003-10-06 Glaxo Group Ltd Pirimidinaminas como moduladores de angiogenesis.
US7235576B1 (en) 2001-01-12 2007-06-26 Bayer Pharmaceuticals Corporation Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
FI117667B (fi) 2001-07-05 2007-01-15 Univ Zuerich Farmaseuttinen koostumus, joka soveltuu käytettäväksi ortopediassa ja hammaslääketieteessä
CN1966725A (zh) 2001-10-31 2007-05-23 爱尔康公司 骨形态生发蛋白(bmp)、bmp受体和bmp结合蛋白及它们在诊断和治疗青光眼中的用途
EP1478648B1 (en) 2002-02-01 2014-04-30 ARIAD Pharmaceuticals, Inc. Phosphorus-containing compounds and uses thereof
WO2003064628A2 (en) 2002-02-01 2003-08-07 Curagen Corporation Novel proteins and nucleic acids encoding same
US7045534B2 (en) * 2002-02-12 2006-05-16 The Board Of Trustees Of The Leland Stanford Junior University Methods of reducing angiogenesis
CA2484994C (en) 2002-04-29 2016-06-14 St. Louis University Peptide antagonists of tgf-beta family members and therapeutic uses thereof
WO2004003163A2 (en) 2002-06-27 2004-01-08 University Of Utah Research Foundation Methods and compositions for manipulating the guided navigation of endothelial tubes during angiogenesis
AU2003287444A1 (en) 2002-10-31 2004-05-25 The General Hospital Corporation Repairing or replacing tissues or organs
WO2005010049A2 (en) 2003-07-09 2005-02-03 Eli Lilly And Company Tgf-beta1 ligands
WO2005044849A2 (en) 2003-08-05 2005-05-19 Eli Lilly And Company Lp mammalian proteins; related reagents
EP1697520A2 (en) 2003-12-22 2006-09-06 Xencor, Inc. Fc polypeptides with novel fc ligand binding sites
CA2554703A1 (en) 2004-01-27 2005-12-08 Compugen Ltd. Differential expression of markers in ovarian cancer
WO2005116052A2 (en) 2004-04-27 2005-12-08 Research Development Foundation ANTAGONISM OF TGF-β SUPERFAMILY RECEPTOR SIGNALING
WO2005113590A2 (en) * 2004-05-12 2005-12-01 Acceleron Pharma Inc. Bmp10 propeptides and related methods
JP2008507288A (ja) * 2004-07-23 2008-03-13 アクセルロン ファーマ インコーポレーテッド ＡｃｔＲＩＩ受容体ポリペプチド、方法、および組成物
WO2006091930A2 (en) 2005-02-24 2006-08-31 Massachusetts Eye & Ear Infirmary Methods and compounds for promoting vessel regression
EP2322560B1 (en) * 2005-03-10 2013-09-04 Morphotek, Inc. Anti-mesothelin antibodies
SI2447283T1 (sl) 2005-09-07 2015-12-31 Amgen Fremont Inc. Človeška monoklonska protitelesa proti aktivin receptorski kinazi-1 (ALK-1)
US20070287160A1 (en) 2006-04-21 2007-12-13 Chou Judy H Methods for high throughput screening of cell lines
WO2007143023A1 (en) 2006-05-31 2007-12-13 Beth Israel Deaconess Medical Center Soluble endoglin compounds and uses thereof for the treatment and prevention of cancer
US10059756B2 (en) 2006-11-02 2018-08-28 Acceleron Pharma Inc. Compositions comprising ALK1-ECD protein
US8642031B2 (en) 2006-11-02 2014-02-04 Acceleron Pharma, Inc. Antagonists of BMP9, BMP10, ALK1 and other ALK1 ligands, and uses thereof
KR20170012582A (ko) 2006-11-02 2017-02-02 악셀레론 파마 인코포레이티드 Ａｌｋ１ 수용체 및 리간드 길항제 및 그의 용도
CL2008003302A1 (es) 2007-11-09 2009-03-06 Genentech Inc Uso de una proteina de funsion kinasa 1 similar al receptor de activina (alk-1) y fc (alk1.fc) porque sirve para preparar un medicamento contra tumor,cancer o desordenes proliferativos.
CN105963695A (zh) 2008-05-02 2016-09-28 阿塞勒隆制药公司 用于调节血管发生和周细胞包裹的基于alk1拮抗剂的方法和组合物
EP2291401A2 (en) 2008-05-15 2011-03-09 Acceleron Pharma, Inc. Antagonists of bmp9, bmp10, alk1 and other alk1 ligands, and uses thereof
WO2010060103A1 (en) 2008-11-24 2010-05-27 Loma Linda University Biomarkers for the detection of head and neck tumors
WO2010128158A1 (en) 2009-05-08 2010-11-11 Novartis Ag Diagnostic biomarkers for fibrotic disorders
WO2012106615A1 (en) 2011-02-03 2012-08-09 Xoma Technology Ltd. Methods and materials for enhancing functional protein expression in bacteria
WO2013116781A1 (en) 2012-02-02 2013-08-08 Acceleron Pharma Inc. Alk1 antagonists and their uses in treating renal cell carcinoma
WO2014055869A1 (en) 2012-10-05 2014-04-10 Acceleron Pharma, Inc. Treatment of cancer with alk1 antagonists
AU2014388308A1 (en) 2014-03-28 2016-10-27 Acceleron Pharma, Inc. Use of activin receptor-like kinase 1 (ALK-1) antagonists in the treatment of cancer

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
JPN5009020069; ＤＥ．ＮＯＶＯ　ＣＡＴＡＬＯＧＵＥ , 200103 *
JPN6012069130; Ｃｅｌｌ Ｖｏｌ．７５, 1993, ｐ．６７１-６８０ *
JPN6012069131; Ｒｅｃｏｍｂｉｎａｎｔ　Ｈｕｍａｎ　ＡＬＫ-１　Ｆｃ　Ｃｈｉｍｅｒａ　Ｃａｔａｌｏｇ　Ｎｕｍｂｅｒ．　３７０-ＡＬ *
JPN6012069132; Ｔｈｅ　ＥＭＢＯ　Ｊｏｕｒｎａｌ Ｖｏｌ．２１，　Ｎｏ．７, 2002, ｐ．１７４３-１７５３ *
JPN6012069133; ＣＨＥＳＴ Ｖｏｌ．１２８，　Ｎｏ．６, 2005, ｐ．５８５Ｓ-５９０Ｓ *
JPN6014014492; ＴＨＥ　ＪＯＵＲＮＡＬ　ＯＦ　ＢＩＯＬＯＧＩＣＡＬ　ＣＨＥＭＩＳＴＲＹ Ｖｏｌ．２８０，　Ｎｏ．２６, 2005, ｐ．２５１１１-２５１１８ *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018127471A (ja) * 2006-11-02 2018-08-16 アクセルロン ファーマ， インコーポレイテッド Ａｌｋ１受容体およびリガンドアンタゴニストならびにその使用
JP2018070625A (ja) * 2011-04-20 2018-05-10 アクセレロン ファーマ インコーポレイテッドＡｃｃｅｌｅｒｏｎ Ｐｈａｒｍａ，Ｉｎｃ． エンドグリンポリペプチドおよびその使用
JP2020202844A (ja) * 2011-04-20 2020-12-24 アクセレロン ファーマ インコーポレイテッドＡｃｃｅｌｅｒｏｎ Ｐｈａｒｍａ，Ｉｎｃ． エンドグリンポリペプチドおよびその使用
US10981972B2 (en) 2011-04-20 2021-04-20 Acceleron Pharma Inc. Endoglin polypeptides and uses thereof
JP7097930B2 (ja) 2011-04-20 2022-07-08 アクセレロン ファーマ インコーポレイテッド エンドグリンポリペプチドおよびその使用
US11590201B2 (en) 2013-10-25 2023-02-28 Acceleron Pharma, Inc. Endoglin peptides to treat fibrotic diseases
JP2016036322A (ja) * 2014-08-11 2016-03-22 日本化薬株式会社 血管新生因子と結合するキメラタンパク質
JP2018517664A (ja) * 2015-04-06 2018-07-05 アクセルロン ファーマ， インコーポレイテッド シングルアームｉ型およびｉｉ型受容体融合タンパク質およびその使用

Also Published As

Publication number Publication date
US20130344067A1 (en) 2013-12-26
JP2018127471A (ja) 2018-08-16
AU2007317926A1 (en) 2008-05-15
ES2612755T3 (es) 2017-05-18
US20080175844A1 (en) 2008-07-24
CA2668411C (en) 2020-02-25
IL198522A (en) 2017-06-29
CA2668411A1 (en) 2008-05-15
EP2087001A2 (en) 2009-08-12
IL198522A0 (en) 2011-08-01
JP2020150955A (ja) 2020-09-24
JP6348448B2 (ja) 2018-06-27
JP2013199496A (ja) 2013-10-03
US20170354731A1 (en) 2017-12-14
RU2013134324A (ru) 2015-01-27
KR20090085662A (ko) 2009-08-07
KR101581961B1 (ko) 2016-01-04
EP2087001B1 (en) 2016-10-26
EP3181580A1 (en) 2017-06-21
RU2559532C2 (ru) 2015-08-10
US8455428B2 (en) 2013-06-04
RU2009120695A (ru) 2010-12-10
JP2015143269A (ja) 2015-08-06
CN101652387A (zh) 2010-02-17
KR20170012582A (ko) 2017-02-02
WO2008057461A3 (en) 2009-02-26
DK2087001T3 (en) 2017-02-06
US12144860B2 (en) 2024-11-19
KR20150008889A (ko) 2015-01-23
US20220296708A1 (en) 2022-09-22
MX2009004718A (es) 2009-06-19
BRPI0717964A2 (pt) 2013-12-17
CN111518218A (zh) 2020-08-11
WO2008057461A2 (en) 2008-05-15
IL253035A0 (en) 2017-08-31

Similar Documents

Publication Publication Date Title
JP6348448B2 (ja) Ａｌｋ１受容体およびリガンドアンタゴニストならびにその使用
JP6194302B2 (ja) 血管新生および周皮細胞組成物を調節するための方法および組成物
US9452197B2 (en) Antagonists of BMP9, BMP10, ALK1 and other ALK1 ligands, and uses thereof
JP2015506961A (ja) Ａｌｋ１アンタゴニストおよび腎細胞癌の治療におけるその使用
US20220017600A1 (en) Methods and compositions for modulating angiogenesis and pericyte composition
EP2291401A2 (en) Antagonists of bmp9, bmp10, alk1 and other alk1 ligands, and uses thereof
AU2016247166B2 (en) ALK1 receptor and ligand antagonists and uses thereof
AU2014200003A1 (en) ALK1 receptor and ligand antagonists and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101102

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20101102

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111006

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130107

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130404

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130411

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130502

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130513

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130606

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130613

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130708

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140404

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140624

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140701

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140801

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140808

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140829

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140905

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141006

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150331

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150731

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20150916

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20151113

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20160805